AVITA Medical (RCEL) Cash & Equivalents (2018 - 2025)

AVITA Medical's Cash & Equivalents history runs 8 years deep, the most recent figure standing at $8.4 million for Q4 2025.

• Quarterly Cash & Equivalents fell 40.21% year-over-year to $8.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $8.4 million (down 40.21% YoY) and the FY2025 annual result came in at $8.4 million, down 40.21% from the prior year.
• Cash & Equivalents was $8.4 million for Q4 2025 at AVITA Medical, down from $15.4 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $115.1 million in Q1 2021 and bottomed at $8.4 million in Q4 2025.
• A 5-year average of $32.9 million and a median of $20.3 million in 2022 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2022 — Cash & Equivalents slumped 79.37% — and 2023, when it soared 96.5%.
• AVITA Medical's Cash & Equivalents stood at $55.7 million in 2021, then sank by 74.69% to $14.1 million in 2022, then fell by 19.15% to $11.4 million in 2023, then grew by 23.25% to $14.0 million in 2024, then sank by 40.21% to $8.4 million in 2025.
• Business Quant data shows RCEL's Cash & Equivalents at $8.4 million in Q4 2025, $15.4 million in Q3 2025, and $10.6 million in Q2 2025.